Target Practice: Zeroing in and Eliminating Ovarian Cancer, an Industry Supported Symposium at IGCS 2023
Activity Overview
The GOG Foundation, Inc., and GOG Partners, welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to register for access to the Target Practice: Zeroing in and Eliminating Ovarian Cancer. A Course to Review and Understand the ADC Opportunities That Exist in Ovarian Cancer Enduring Education Materials, an Industry Supported Symposium at the IGCS 2023 Annual Global Meeting in Seoul, South Korea.
Antibody drug conjugates are targeted chemotherapy for treating ovarian and other cancers; however, there are so many new and emerging therapies, how do you decide which one is best for the treatment and care of your patient? In this course, physician experts in the field of ADCs will discuss the ADCs that are currently available or under study for treatment of ovarian cancer, describe and outline the mechanism of action for each, identify the most promising targets and payloads and discuss how to mitigate adverse events. The physician faculty will also discuss the future of ADC development including how molecular profiling may change and drive use of ADCs to earlier lines of therapy.
The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: ImmunoGen, Mersana, and Novocure.
Target Audience
The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.
Learning Objectives
The purpose of this program is to help physicians better understand newly approved ADCs and combinations available and under development for the treatment of patients with ovarian cancer. Physicians and healthcare personnel who treat gynecologic malignancies will be provided a comprehensive overview about the latest treatment strategies during this 90-minute program. Leaders in the field of ovarian cancer will review data, discuss opportunities that are under development.
Upon completion of the activities in this series, learners will demonstrate:
-
- Review and understand all ADC Opportunities that exist in ovarian cancer patient care management.
- Understand the components of each unique agent and how to mitigate any adverse reactions.
- Discuss ADC targets and how to prioritize targets for your patient.
- Outline the ongoing trials studying ADCs in Ovarian Cancer
To participate in person for this non-CME Symposium, attendees must be registered to attend the IGCS 2023 Annual Global Meeting. This session is not included in main conference CME/CPD credit.
Moderator
Dr. Kathleen Moore
Faculty
Dr. Linda Duska
Dr. Roisin E. O’Cearbhaill
Dr. Isabelle Ray-Coquard
Agenda & Presentation Materials
Target Practice: Zeroing in and Eliminating Ovarian Cancer. A Course to Review and Understand the ADC Opportunities That Exist in Ovarian Cancer., an Industry Supported Symposium at the IGCS 2023 Annual Global Meeting
Presented on Monday, November 6, 2023 from 12:40 – 14:10 KST
Kathleen Moore, MD, University of Oklahoma, Stephenson Cancer Center, USA
Isabelle Ray-Couqard, MD, PhD, Centre Léon Bérard, France
Linda Duska, MD, University of Virginia School of Medicine, USA
All Faculty
Róisín O’Cearbhail, MD, Memorial Sloan Kettering Cancer Center, USA
All Faculty
Technical Requirements
This virtual activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers.